Home/Targazyme/Lynnet Koh

LK

Lynnet Koh

Chairman & CEO

Therapeutic Areas

Oncology Autoimmune Diseases Neurodegenerative Diseases

Targazyme Pipeline

Drug	Indication	Phase
TZ-101 Platform	Cell Therapy Enhancement (Oncology, Autoimmune, Neurodegenerative)	Pre-clinical

Leadership Team at Targazyme

Chuck Olson, PhD

Chief Technology Officer

Acting Chief Medical Officer & Medical Board Chair

Rodger McEver, MD

Scientific Founder, Board Member

Lijun Xia, MD, PhD

Scientific Founder, Board Member

View full Targazyme profile